Quoin pharmaceuticals announces submission of ind for its lead asset, qrx003, for netherton syndrome

Quoin anticipates initiating clinical testing in q2 2022 quoin anticipates initiating clinical testing in q2 2022
QNRX Ratings Summary
QNRX Quant Ranking